Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Novel Communications in Diabetes

A Psychoeducational Program to Restore Hypoglycemia Awareness: The DAFNE-HART Pilot Study

  1. Nicole de Zoysa1,
  2. Helen Rogers2,
  3. Marietta Stadler1,
  4. Carla Gianfrancesco3,
  5. Susan Beveridge3,
  6. Emma Britneff1,
  7. Pratik Choudhary1,
  8. Jackie Elliott4,
  9. Simon Heller4 and
  10. Stephanie A. Amiel1⇑
  1. 1Diabetes Research Group, King’s College London, London, U.K.
  2. 2King’s College Hospital NHS Foundation Trust, London, U.K.
  3. 3Sheffield Teaching Hospitals NHS Trust, Northern General Hospital, Sheffield, U.K.
  4. 4Sheffield University School of Medicine, Academic Unit of Diabetes, Endocrinology, and Metabolism, School of Medicine and Biomedical Sciences, Sheffield, U.K.
  1. Corresponding author: Stephanie A. Amiel, stephanie.amiel{at}kcl.ac.uk.
Diabetes Care 2014 Mar; 37(3): 863-866. https://doi.org/10.2337/dc13-1245
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Abstract

OBJECTIVE To develop and pilot a novel intervention addressing motivational and cognitive barriers to avoiding hypoglycemia in people with type 1 diabetes and persistent impaired awareness of hypoglycemia (IAH) despite training in flexible insulin therapy.

RESEARCH DESIGN AND METHODS A 6-week intervention using motivational interviewing and cognitive behavioral techniques was designed. Diabetes educators were trained and supported in its delivery to 23 people with IAH (Gold score ≥4).

RESULTS Twelve months postcourse, hypoglycemia awareness had improved (P < 0.001). Median (range) rates of severe hypoglycemia (SH) fell from 3 (0–104) to 0 (0–3) per person per year (P < 0.0001) and moderate from 14 (0–100) to 0 (0–18) per person per 6 weeks (P < 0.001). Worry and behavior around hyperglycemia improved. HbA1c was unchanged.

CONCLUSIONS A pilot intervention targeting motivation and cognitions around hypoglycemia engaged patients with resistant IAH and recurrent SH and was associated with significant improvement, supporting the hypothesis that these factors underpin problematic hypoglycemia.

Introduction

Hypoglycemia and fear of hypoglycemia remain major barriers to achieving optimal glucose control and quality of life for people with type 1 diabetes. Structured education in flexible insulin therapy (e.g., the U.K.’s Dose Adjustment for Normal Eating [DAFNE]) and/or use of insulin pump therapy reduces severe hypoglycemia (SH) (1), but some continue to experience impaired awareness of hypoglycemia (IAH) with high rates of SH, their problematic hypoglycemia resistant to intervention. We hypothesized that many such people have motivational and cognitive barriers to hypoglycemia avoidance and resolution of IAH. We designed and piloted an intervention using motivational interviewing and cognitive behavioral theory targeting these barriers.

Research Design and Methods

An intervention, teaching aids, curriculum, and manual (DAFNE-Hypoglycemia Awareness Restoration Training [DAFNE-HART]) were designed by a clinical psychologist, doctors, educators, and patient representatives. It revised relevant sections from DAFNE and interventions targeting problematic hypoglycemia (2,3). Participants were taught to look for hypoglycemia cues and consider their own causes and consequences of IAH and how to reduce hypoglycemia exposure. The educational material was presented within a motivational interviewing framework to support behavior change and minimize resistance. Cognitive behavioral techniques were used to identify and restructure unhelpful thoughts such as needing to “soldier on” through episodes, underestimating the consequences of hypoglycemia, and worrying excessively about intermittent hyperglycemia. In three weekly full-day group sessions, theories about hypoglycemia and awareness were reviewed, the concept of a “body scan” (a structured guide to find subjective cues to blood glucose concentration) was taught, insulin action was revised, and theories linking thoughts with behavior were explored, supporting patients to recognize and challenge their own cognitions around hypoglycemia. “Homework” used home glucose monitoring to test the learning and, during weeks 4 and 5, try newly learned skills/strategies, with scheduled individual face-to-face and telephone support. A final full-day group session focused on relapse prevention.

Twenty-four people (12 male) with type 1 diabetes, using DAFNE principles for insulin self-adjustment, with persistent IAH assessed clinically and scoring ≥4 on the Gold score, in which patients rate their awareness of hypoglycemia from 1 (“I am always aware of my hypoglycemia”) to 7 (“I am never aware of my hypoglycemia”) (4), were recruited. Hypoglycemia experience, including self-report of SH (hypoglycemia [<63 mg/dL/3.5 mmol/L] that could not be self-treated, requiring assistance), over the preceding 12 months and moderate hypoglycemia (<63 mg/dL/3.5 mmol/L, self-treated but disrupting daily activity) over the last 6 weeks, hypoglycemia awareness and burden (Gold, Clarke, and Ryan scores) (4–6), and mood and self-care behaviors around glucose control were documented by questionnaires, including the Hospital Anxiety and Depression Scale (HADS) (7), the Problem Areas In Diabetes (PAID) Questionnaire (8), the Hypoglycemia Fear Survey II (9), and the Hyperglycemia Avoidance Score (courtesy of L. Gonder-Frederick, University of Virginia, Charlottesville, VA), and glycated hemoglobin (HbA1c) was measured. At baseline and 3 months postcourse, up to 6 days continuous glucose monitoring (CGM) (Medtronic, Inc.) was performed. Participants were reassessed 12 months postcourse.

Five DAFNE educators (specialist nurses and dietitians) were trained in the curriculum and relevant psychological skills in a 2-day workshop. They delivered four courses with weekly supervision (face-to-face, telephone, and e-mail) from a clinical psychologist.

The protocol was approved by the National Research Ethics Committee London. King’s College Hospital NHS Foundation Trust sponsored the protocol. Participants provided written informed consent. Data were compared using Student t, Wilcoxon signed rank (nonparametric variables), and χ2 or related samples McNemar (categorical variables or when including episodes of no incidence) tests, using IBM SSPS version 4. Hypoglycemia in valid CGM data was defined as <3 mmol/L for ≥20 min. P < 0.05 was considered significant.

Results

All participants completed courses. One missed follow-up and two returned only SH and HbA1c data at 12 months. Mean (±SD) age for the 23 completers was 54.4 ± 7.9 years; diabetes duration 30.7 ± 11.9 years; time since DAFNE 7.1 ± 4.1 years. Fifteen were using twice-daily background and premeal quick-acting insulin injections, and eight were using insulin pumps. None had renal impairment, hypoadrenalism, hypothyroidism, or growth hormone deficiency. All described themselves as having “impaired awareness,” not experiencing symptoms with a blood glucose <54 mg/dL (3 mmol/L) when awake. Their SH in the year before, defined above, included 14 participants reporting unconsciousness (0–30/participant, median 1), 3 attending emergency departments (one 24 times), and 3 admissions. Nineteen people answering the question reported an additional six ambulance call-outs.

Twelve months postcourse, rates of severe and moderate hypoglycemia fell (Table 1). Seventeen participants reported no further SH (P < 0.0001). Measures of awareness improved (Table 1), with 9 of 20 regaining awareness with Gold and/or Clarke scores <4 (P < 0.04 vs. baseline for either) and 8 of 20 reporting no episodes of hypoglycemia (<54 mg/dL) without symptoms vs. none precourse (Table 1). Behavior scores around hyperglycemia avoidance improved and worry scores about hyperglycemia reduced significantly. Worries around hypoglycemia tended to reduce. PAID scores improved. HbA1c did not deteriorate.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1

Pre- and postcourse demographic and biomedical data and anxiety, depression, and behavioral scores

At 3 months postcourse, the duration of daytime hypoglycemia on CGM fell and hypoglycemia burden (Ryan score) fell from equivalent to people registering for islet transplantation toward that of routine clinic populations (6).

Conclusions

The main defense against hypoglycemia during insulin treatment of type 1 diabetes is subjective awareness of a falling blood glucose, impaired awareness being associated with a sixfold increase in SH (10). Awareness can be improved by hypoglycemia avoidance (e.g., 11). Retraining patients in insulin self-adjustment (1), training in hypoglycemia recognition and avoidance, as provided by Blood Glucose Awareness Training (BGAT) and Hypoglycemia Anticipation, Awareness and Treatment Training (HAATT) (2,3), and insulin pump therapy (12) all reduce SH. DAFNE restores awareness to 43% of people with IAH (1). Continuous glucose sensing reduces SH without restoring awareness (13). A group of people remain resistant to interventions to restore hypoglycemia awareness and continue to experience SH. We hypothesized that these patients have cognitive and motivational barriers to hypoglycemia avoidance, based on neuroimaging showing different activation in reward pathways during hypoglycemia in people with IAH, qualitative research describing patient beliefs about hypoglycemia awareness, and clinical audit (14–16). Although we cannot attribute outcomes to particular elements of the intervention from this uncontrolled pilot, the preliminary evidence of reduced hypoglycemia and increased awareness suggests that addressing beliefs and motivation is very relevant to this population.

The novelty of our intervention lies in the following: first, in training diabetes educators in motivational interviewing to address resistance around behavior change that might have occurred and did occur; second, in providing educators with basic cognitive behavioral therapy skills to provide patients with an explicit model of how thoughts can influence behavior; and third, in offering accessible visual metaphors (e.g., the ostrich burying its head in the sand for underestimation of the impact of hypoglycemia) by which patients could identify their own “thinking traps” and explore alternatives. Although additional technologies addressing hypoglycemia, such as pumps, sensors, and islet transplantation, were available at our centers, few of our patients had accessed them; some were more open to these after DAFNE-HART. This, together with the evidence of behavior change described above, suggests that people may be more ready to use additional technologies to address problematic hypoglycemia if motivational factors to regain awareness are addressed.

These data are from a pilot: small patient numbers and not controlled for the impact of the educational element alone. The early evidence of success supports a key role for cognitive barriers in apparently intractable IAH. The intervention now requires refinement, based on participant (patients and educators) experiences, and testing in a randomized, controlled trial. It has potential to be delivered at scale by existing diabetes educators, trained and supported by clinical psychologists, rather than requiring referral to a new cadre of diabetes-experienced psychologists. Meanwhile, we conclude that motivational and cognitive barriers to hypoglycemia avoidance in people with significantly impaired hypoglycemia awareness are legitimate therapeutic targets.

Article Information

Acknowledgments. The authors are very grateful to D. Cox and L. Gonder-Frederick (both of University of Virginia, Charlottesville, VA) for advice and assistance in preparing the intervention and the generous gift of questionnaires to assess fear of hypoglycemia and hyperglycemia. The authors are also grateful to Dr. K. Winkley (King’s College London) and Dr. C. Emery (University of Sheffield) (research managers for the National Institute for Health Research [NIHR] programme grants RP-PG-0606-1142 and RP-PG-0606-1148) for their support in administering the educator training and validation, D. Fairbairn and M. Patterson (members of the DAFNE User Advisory Group [DUAG], supported by the Central DAFNE Office, Northumbria Healthcare Foundation Trust, Northumbria, U.K.) for helping in the course development, and educators V. Francis and P. Marks (King’s College Hospital NHS Foundation Trust) for help in delivering courses. The authors also thank the people with diabetes who contributed to and participated in this pilot study.

Funding. This study contains independent research funded by the NIHR under its Programme Grants for Applied Research scheme (RP-PG-0606-1142 and RP-PG-0606-1148).

Duality of Interest. S.H. has undertaken consultancy on behalf of Eli Lilly and Company, Novo Nordisk, Sanofi, and LifeScan, for which his institution has received payment, and spoken on behalf of Eli Lilly and Company and Novo Nordisk, for which he has received payment. P.C. has undertaken consultancy on behalf of and/or received speaker fees from Novo Nordisk, Eli Lilly and Company, Johnson & Johnson, Medtronic, and Merck Sharp & Dohme. No other potential conflicts of interest relevant to this article were reported.

Author Contributions. N.d.Z. designed the intervention and supervised its implementation and drafted the manuscript. M.S. conducted the analysis of the 12-month data and assisted in its collection. H.R., P.C., and J.E. contributed to the protocol and the construction of the intervention and its delivery and analyzed data. C.G., S.B., and S.H. contributed to the protocol and the construction of the intervention and its delivery. E.B. analyzed data and created the database for the analysis. S.A.A. contributed to the protocol and the construction of the intervention and its delivery, created the database for the analysis, and drafted the manuscript. All the listed authors made substantial contributions to the study design, performance, and/or analysis and contributed to and/or reviewed and revised the final manuscript. S.A.A. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Prior Presentation. This study was presented in oral form at the 73rd Scientific Sessions of the American Diabetes Association, Chicago, IL, 21–25 June 2013.

Footnotes

  • The views expressed in this article are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.

  • Received May 27, 2013.
  • Accepted October 28, 2013.
  • © 2014 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

References

  1. ↵
    1. Hopkins D,
    2. Lawrence I,
    3. Mansell P,
    4. et al
    . Improved biomedical and psychological outcomes 1 year after structured education in flexible insulin therapy for people with type 1 diabetes: the U.K. DAFNE experience. Diabetes Care 2012;35:1638–1642pmid:22619082
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Cox DJ,
    2. Gonder-Frederick L,
    3. Polonsky W,
    4. Schlundt D,
    5. Kovatchev B,
    6. Clarke W
    . Blood glucose awareness training (BGAT-2): long-term benefits. Diabetes Care 2001;24:637–642pmid:11315822
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Cox DJ,
    2. Kovatchev B,
    3. Koev D,
    4. et al
    . Hypoglycemia anticipation, awareness and treatment training (HAATT) reduces occurrence of severe hypoglycemia among adults with type 1 diabetes mellitus. Int J Behav Med 2004;11:212–218pmid:10388961
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Gold AE,
    2. MacLeod KM,
    3. Frier BM
    . Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care 1994;17:697–703pmid:7924780
    OpenUrlAbstract/FREE Full Text
    1. Clarke WL,
    2. Cox DJ,
    3. Gonder-Frederick LA,
    4. Julian D,
    5. Schlundt D,
    6. Polonsky W
    . Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care 1995;18:517–522pmid:7497862
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Ryan EA,
    2. Shandro T,
    3. Green K,
    4. et al
    . Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes 2004;53:955–962pmid:15047610
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Zigmond AS,
    2. Snaith RP
    . The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361–370pmid:6880820
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Polonsky WH,
    2. Anderson BJ,
    3. Lohrer PA,
    4. et al
    . Assessment of diabetes-related distress. Diabetes Care 1995;18:754–760pmid:7555499
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Gonder-Frederick LA,
    2. Schmidt KM,
    3. Vajda KA,
    4. et al
    . Psychometric properties of the hypoglycemia fear survey-ii for adults with type 1 diabetes. Diabetes Care 2011;34:801–806pmid:21346182
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Geddes J,
    2. Schopman JE,
    3. Zammitt NN,
    4. Frier BM
    . Prevalence of impaired awareness of hypoglycaemia in adults with type 1 diabetes. Diabet Med 2008;25:501–504pmid:18387080
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Cranston I,
    2. Lomas J,
    3. Maran A,
    4. Macdonald I,
    5. Amiel SA
    . Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. Lancet 1994;344:283–287pmid:7914259
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Pickup JC,
    2. Sutton AJ
    . Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008;25:765–774pmid:18644063
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Ly TT,
    2. Nicholas JA,
    3. Retterath A,
    4. Lim EM,
    5. Davis EA,
    6. Jones TW
    . Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA 2013;310:1240–1247pmid:24065010
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Dunn JT,
    2. Cranston I,
    3. Marsden PK,
    4. Amiel SA,
    5. Reed LJ
    . Attenuation of amydgala and frontal cortical responses to low blood glucose concentration in asymptomatic hypoglycemia in type 1 diabetes: a new player in hypoglycemia unawareness? Diabetes 2007;56:2766–2773pmid:17660265
    OpenUrlAbstract/FREE Full Text
    1. Smith CB,
    2. Choudhary P,
    3. Pernet A,
    4. Hopkins D,
    5. Amiel SA
    . Hypoglycemia unawareness is associated with reduced adherence to therapeutic decisions in patients with type 1 diabetes: evidence from a clinical audit. Diabetes Care 2009;32:1196–1198pmid:19389817
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Rogers HA,
    2. de Zoysa N,
    3. Amiel SA
    . Patient experience of hypoglycaemia unawareness in type 1 diabetes: are patients appropriately concerned? Diabet Med 2012;29:321–327pmid:21913969
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Diabetes Care: 37 (3)

In this Issue

March 2014, 37(3)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A Psychoeducational Program to Restore Hypoglycemia Awareness: The DAFNE-HART Pilot Study
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A Psychoeducational Program to Restore Hypoglycemia Awareness: The DAFNE-HART Pilot Study
Nicole de Zoysa, Helen Rogers, Marietta Stadler, Carla Gianfrancesco, Susan Beveridge, Emma Britneff, Pratik Choudhary, Jackie Elliott, Simon Heller, Stephanie A. Amiel
Diabetes Care Mar 2014, 37 (3) 863-866; DOI: 10.2337/dc13-1245

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

A Psychoeducational Program to Restore Hypoglycemia Awareness: The DAFNE-HART Pilot Study
Nicole de Zoysa, Helen Rogers, Marietta Stadler, Carla Gianfrancesco, Susan Beveridge, Emma Britneff, Pratik Choudhary, Jackie Elliott, Simon Heller, Stephanie A. Amiel
Diabetes Care Mar 2014, 37 (3) 863-866; DOI: 10.2337/dc13-1245
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Research Design and Methods
    • Results
    • Conclusions
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Stay-at-Home Orders During the COVID-19 Pandemic, an Opportunity to Improve Glucose Control Through Behavioral Changes in Type 1 Diabetes
  • Fully Closed Loop Glucose Control With a Bihormonal Artificial Pancreas in Adults With Type 1 Diabetes: An Outpatient, Randomized, Crossover Trial
  • Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up
Show more Novel Communications in Diabetes

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.